

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2026

NRX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-38302	82-2844431
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)
1201 Orange Street, Suite 600 Wilmington, Delaware		19801
(Address of principal executive offices)		(Zip Code)

(484) 254-6134
(Registrant's telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.424)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of exchange on which registered
Common Stock, par value \$0.001 per share	NRXP	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 8, 2026, representatives of NRx Pharmaceuticals, Inc. (the “Company”) used the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K in connection with presentations and meetings with investors and other persons. The Company may continue to use the investor presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and other persons.

The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Investor Presentation
104	Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NRx Pharmaceuticals, Inc.

Date: September 14, 2026

By: /s/ Jonathan Javitt
Name: Jonathan Javitt
Its: Chief Executive Officer



GeNeuro
An NRx Company

HERV Drugs that May Change Humanity



A treatment for **ALS**
by **2029**



SEPTEMBER 2026



GeNeuro
An NRx Company

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of historical fact, including statements regarding our future results of operations and financial position, business strategy, drug discovery and development plans, regulatory plans, clinical trial plans and timing, objectives, potential market opportunities, competitive position, and plans and objectives of management for future operations, are forward-looking statements. These forward-looking statements are based on management's current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to our ability to discover and develop products, preclinical and clinical results varying from expectations, regulatory actions, competition, our ability to protect intellectual property, our need for additional financing, and market conditions.

Forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investors are cautioned not to place undue reliance on these forward-looking statements.

September 2026

WHAT IF THE WORST DISEASES IN HUMANITY ARE CAUSED BY **ANCIENT VIRUSES** THAT ALREADY LIVE IN OUR DNA?

THE HIDDEN THREAT

Ancient viruses are not gone.
They are part of us.



CANCER

HERVs can activate genes that drive uncontrolled cell growth.



NEUROLOGICAL DISORDERS

Linked to MS, ALS, Schizophrenia, Autism, and more.



AUTOIMMUNE DISEASES

HERVs may trigger the immune system to attack the body.



CHRONIC INFLAMMATION

A silent driver of many modern illnesses.



THE PATH TO THE CURE

We can learn to control what
our ancestors couldn't.



IDENTIFY

Discover which viral sequences drive disease.



CONTROL

Silence or modulate harmful viral activity with precision.



RESTORE

Rebalance immune function and cellular health.



HEAL

Unlock new treatments for today's most devastating diseases.



GeNeuro
An NRx Company

WHAT IF WE HAVE A PATH TO THE CURE?

SCIENCE IS REVEALING THE CODE. HUMANITY CAN WRITE THE FUTURE.

THE HIDDEN 8%: FROM "JUNK DNA" TO THE DARK GENOME

A REVOLUTION IN OUR UNDERSTANDING OF HUMAN DNA

THE OLD DOGMA

FOR DECADES, WE WERE TAUGHT...

8% of our genetic code was considered useless—evolutionary debris with no function.

92%
USEFUL DNA

8%
"JUNK DNA"

DISMISSED AS
DORMANT
"JUNK DNA"

SCIENCE
EVOLVES

THE NEW PARADIGM

RECENT RESEARCH REVEALS...

That 8% is not empty. It is a vast, functional "dark genome" composed of ancient viral sequences called HERVs.

8%
THE DARK
GENOME
HERVs

Human Endogenous Retroviruses (HERVs) are fossilized remnants of ancient viral infections integrated into our lineage over millions of years.

THE MISCONCEPTION

- ✗ No known function
- ✗ Evolutionary noise
- ✗ Genetic dark matter

THE EMERGING TRUTH

- ✓ Many HERVs retain functional open reading frames
- ✓ Epigenetically reactivatable
- ✓ Potent genetic switches

CAN DRIVE:



DEVELOPMENT



DISEASE
including cancer, autoimmune disorders, and neurological conditions



HUMAN ENDOGENOUS RETROVIRUSES (HERVs)

THE HIDDEN THREAT IN ALL HUMAN DNA

HERVs ARE A MISSING LINK IN THE CAUSE OF MAJOR NEURODEGENERATIVE DISEASES



You don't "catch" a HERV infection. HERVs are no longer capable of forming infectious virus particles.



It's the replication of **HERV envelope protein** that causes havoc.




The HERV envelope protein is highly **neuroinflammatory**.



Blood levels of HERV Env associated with **Schizophrenia, Multiple Sclerosis, Alzheimer's, Autism, ALS** and other **CNS diseases**.



Viral infections and other triggers may cause **HERV replication**.



HERVs may be a **silent driver** behind many of humanity's most devastating **brain and immune diseases**.



ALS



MULTIPLE SCLEROSIS



SCHIZOPHRENIA




ALZHEIMER'S DISEASE



AUTISM

WHAT MAKES UP OUR GENOME?



**nature
medicine**

The enemy within:
dormant retroviruses awaken
Engel & Hiebert,
Nature Medicine, 2010

Sources: Regulatory evolution of innate immunity through co-option of endogenous retroviruses; Science, Vol. 351, Issue 6277

Discovery of unfixed endogenous retrovirus insertions in diverse human populations. Proc Natl Acad Sci U S A. 2016

Human Endogenous Retrovirus Type W Envelope Protein Inhibits Oligodendroglial Precursor Cell Differentiation; Ann Neurol. 2013;74 (5) A

GeNeuro
An NRx Company

HUMANS HAVE CO-OPTED HERV PROTEINS


HERV CO-OPTION: A KEY TO HUMAN EVOLUTION

1. FOSSILIZED ANCIENT VIRUSES (~30-20 MYA)


HERVs are integrated remnants of ancient viral infections. Most are degraded and mutated.




2. CO-OPTION OF HERV SEQUENCES



A. PLACENTAL FUNCTION



B. BRAIN COMPLEXITY



3. POTENTIAL ROLE IN COMBATING INFECTIONS



4. INFLAMMATION & AUTOIMMUNITY



HERV PROTEINS CAN ALSO HAVE A DARK SIDE

THE DARK SIDE OF HERVs: DYSREGULATION IN PATHOLOGY

HERV ACTIVATION IN THE GENOME



HERV DYSREGULATION



ALS & HERV-K ACTIVATION

1. Motor Neuron Degeneration
2. TDP-43 Protein Mislocalization & Aggregation
3. HERV-K Env protein accumulation in Motor Cortex (highlight) and Spinal Cord

ALS patients show elevated HERV-K in serum & CSF, promoting neurotoxicity.
↳ HERV-K Env in Serum/CSF

MS & HERV-W DEMYELINATION

1. Autoimmune Demyelinating Plaques
2. Chronic Neuroinflammation
3. HERV-W Env (MSRV) on demyelinating cells and immune infiltration

MS patients exhibit HERV-W Env, triggering neuroinflammation and myelin damage.
↳ HERV-W Env in Serum/CSF

PSYCHOSIS & BRAIN DYSFUNCTION

1. Altered Connectivity
2. Dopamine Dysregulation
3. HERV-W Env expressed in Prefrontal Cortex and Ventricles

Schizophrenia and acute psychosis are linked to elevated HERV-W, affecting neurodevelopment and function.
↳ HERV-W Env in Serum/CSF

CANCER & HERV-DRIVEN PATHWAYS

1. Proliferation & Metastasis
2. Immune Evasion
3. HERV-K Env on tumor cells (e.g., Breast Cancer, Melanoma)

HERV-K Env expression is associated with cancer progression and poor
↳ HERV-K Env in Tumor/Serum



GeNeuro
An NRX Company

SCIENCE IS REVEALING THE CODE. HUMANITY CAN WRITE THE FUTURE.

WHAT IS ALS?

A relentlessly progressive disease
of the **motor neurons**



**MOTOR NEURON
DEGENERATION**



**PARALYSIS &
RESPIRATORY FAILURE**



6,000
NEW U.S. CASES EACH YEAR



3-5 YEARS
SURVIVAL AFTER DIAGNOSIS



GeNeuro
An NRx Company

SCIENCE IS REVEALING THE CODE. HUMANITY CAN WRITE THE FUTURE.


AUGUST 2026

7



Evidence that HERV-K Envelope Protein Causes ALS and Anti-HERV-K Env Might Prevent Degeneration

Amyotrophic Lateral Sclerosis (ALS)



Progressive motor neuron degeneration

Degeneration of neurons in the motor cortex (upper motor neurons) and spinal cord (lower motor neurons).



HERV-K envelope protein is found in CSF of >75% of ALS patients



HERV-K Envelope Protein in CSF

>75% of ALS patients have detectable HERV-K envelope protein in CSF



HERV-K Envelope Protein

Causes neurotoxicity in mice and in human motor neuron cell culture



CSF from ALS Patients

Causes neurotoxicity in mice and in human motor neuron cell culture



Anti-HERV-K MAb (GNK-301)

Blocks neurotoxicity in mice and in human motor neuron cell culture



THREE WAYS TO COUNTER A NEUROTOXIC PROTEIN

Intervene at the DNA, RNA, or protein level



MABS: A PROVEN PRECISION PLATFORM

7 OF 10

best-selling drugs were antibody biologics in 2018

Humira • Avastin • Keytruda

WHY MABS

High molecular specificity can limit off-target toxicity

Specificity is a safety advantage—not a guarantee of safety.



GeNeuro
An NRx Company

August 2026

11



ALS DEVELOPMENT TIMELINE



MAY 2026



GeNeuro
An NRx Company

13




Tofersen (Qalsody)

An FDA Case Study

Use of a Surrogate Endpoint to Demonstrate Substantial Evidence of Effectiveness for an Accelerated Approval

1. ALS is a serious condition with a lack of available therapies, and
2. Tofersen had an effect on a surrogate endpoint, NfL, that is reasonably likely to predict clinical benefit.



Tofersen was approved for ALS patients with SOD 1 mutation (5% of all ALS) based on a 28 week 108 person trial



A \$25mm Path to a Humanity-Changing Drug in 2029



ADVANCED DEVELOPMENT

The antibody is fully developed and will be manufactured by July 2027



LOW PRECLINICAL BARRIER

FDA has substantially reduced preclinical toxicology requirements for MAbs



PRIOR PATIENT EXPERIENCE

HERV-W MAb has already been in 500 patients without toxicity



ACCELERATED APPROVAL PRECEDENT

FDA has already approved an ALS drug based on the NFL biomarker



SEPT 2026



GeNeuro
An NRx Company



Funding Pathway to Drug Approval



\$80 million has been added to the 2027 Defense Budget to support Clinical Trials in ALS

SEPT 2026

*anticipated



GeNeuro
An NRx Company



GeNeuro LEADERSHIP

VISIONARY LEADERSHIP. SCIENTIFIC EXCELLENCE. TRANSFORMING LIVES.

LEADERSHIP TEAM



**Jonathan C. Javitt,
MD, MPH
CEO**

Forty years of experience in biotechnology, drug development and public policy, including prior FDA approvals for monoclonal/ aptamer drugs in human disease. Seven public company exits in pharmaceuticals, medical devices, and healthcare technology. White House appointee in four Presidential Administrations.



**Michael D. Taylor
CFO**

Financial executive with over 30 years of experience in biotechnology and healthcare, including public company finance, capital markets, and strategic planning. Expert in building strong financial infrastructure to support discovery and growth.



**Riccardo Panicucci,
Ph.D.
CTO**

Experienced biotechnology executive and scientist with deep expertise in antibody discovery, biomarker development, and translational research. Leads GeNeuro's R&D strategy and technology innovation to advance next-generation therapeutics.



**Philip Lavin, PhD, FACA, FRAPS,
Lead Methodologist**

World-renowned expert in research methodology and biostatistics. Lead statistician on more than 80 new drug, device, and biologics approvals. Adjunct Professor Harvard Medical School and Brigham and Women's Hospital.

SCIENTIFIC ADVISORY BOARD



**Arnold Levine, PhD
Chair**

Professor Emeritus, Institute for Advanced Study. Internationally recognized for pioneering research in molecular biology. Founding Chair, Molecular Biology, Princeton University. Former President, Rockefeller University.



**Avindra Nath, MD, PhD
Co-Chair Neurology**

Chief, Clinical Neurovirology Section, NINDS, NIH. International leader in neurovirology and its role in neurological diseases. Renowned for groundbreaking research and clinical insights.



**Marion Leboyer, MD, PhD
Co-Chair Psychiatry**

Professor of Psychiatry, Université Paris Cité. World-leading expert in psychiatric disorders, genetics, and translational research. Provides strategic guidance on advancing understanding and treatment of complex neuropsychiatric conditions.



**Wayne Pines, MD
Former Associate
Commissioner, FDA**

Regulatory and public-affairs expert and former FDA Associate Commissioner, with deep experience in FDA communications, policy, and product-approval strategy.



GeNeuro collaborates with leading organizations and experts to advance innovative research, accelerate discovery, and improve outcomes for patients with neurologic diseases.



National Institute for Neurologic Diseases and Stroke

Through NIH/NINDS, GeNeuro has received grant funding and collaborates on research to advance therapies for ALS and other neurologic disorders.



CDMRP

Congressionally Directed Medical Research Programs

Congressionally Directed Medical Research Program

GeNeuro has received peer-reviewed funding through the CDMRP to support research into HERV technologies and therapeutic development for neurologic conditions.



NEALS

Network of Excellence for ALS

NEALS Network of Excellence for ALS

GeNeuro is an active member of the NEALS Network, working alongside leading academic and industry experts to accelerate ALS research and drug development.



Target ALS

GeNeuro collaborates with Target ALS to accelerate the development of novel therapies and improve outcomes for people living with ALS.



Hyman Phelps McNamara

Regulatory Consultants

Hyman Phelps McNamara (Regulatory Consultants)

Expert regulatory guidance to support GeNeuro's global development strategy and interactions with regulatory authorities.



ICM

Paris Brain Institute

Paris Brain Institute

Collaborating to advance research on neurologic diseases and accelerate translational science from bench to bedside.



University of Basel

University of Basel

Academic collaboration advancing innovative research in immunology and neurologic disease mechanisms.

POLYMUN

VIENNA

Polymun (Vienna)

Strategic collaboration to leverage expertise in immunology and antibody engineering for the development of next-generation therapeutics.

FONDATION FondaMental

RÉSEAU DE COOPÉRATION SCIENTIFIQUE EN SANTÉ MENTALE

Fondation FondaMental

Collaborating to advance research in psychiatry and neurologic disorders and support innovative therapeutic approaches.



Our partnerships drive innovation, de-risk development, and deliver value for patients.

Together, we are advancing breakthrough solutions for some of the most devastating neurologic diseases.



SEPT 2026



GeNeuro
An NRx Company

16



15 YEARS OF DEVELOPMENT IN SWITZERLAND AND EUROPE OVER **EU 150MM** IN PRIOR INVESTMENT

GeNeuro USA (an NRx Company) awarded all assets of Geneuro, SA



Global Patent Portfolio covering antibodies and diagnostic tests, IP partnership with **NIH** and **French Universities**



Temelimab (anti HERV W antibody) has **complete IMPD** and is clinical stage in **EMA** and **Switzerland**



In-vitro diagnostic tests (gel electrophoresis) are validated for **HERV-W** and **HERV-K** envelope protein



GMP monoclonal antibody for ALS (GNK-301) is ready to enter the clinic in the **US**



6 month primate tox and **3 completed** European phase 2a trials in **Type I Diabetes**, **Multiple Sclerosis**, and **COVID** sequelae



Nonclinical proof of concept in **Schizophrenia**, **Mania**, **Autism**, and **ALS**



SEPTEMBER 2026



GeNeuro
An NRx Company

10



Clinical-stage targets for HERV-mediated diseases

Clinical Target	Pre-clinical	Phase I	Phase IIa	Phase IIb	Phase III
 1. HERV-K in ALS	 • CRADA Agreement with NIH in ALS. Orphan indication • Joint patent issued with NIH • Planning clinical initiative			 GMP antibody expected July 2027	
 2. Psychosis	 • Planning discussions with FDA to design a proof-of-concept study • MS clinical trials provide phase I safety exposures.				
 3. Multiple Sclerosis	 270 patients / 50 centers in the RRMS indication completed March 2018. • Demonstrated statistically significant reduction in brain "black holes" on MRI • Demonstrated attenuated significant loss of brain volume compared to placebo • MS clinical trials provide phase I safety exposures.				
 4. Type I Diabetes	 Proof-of-concept Phase IIa • Completed in Australia, promising findings in islet cell preservation, ready for Phase 2b/3.				
 5. COVID Sequelae	 Phase 2 in Long COVID complete • Missed primary endpoint • Evidence of beneficial mental status effects				



September 2026



GeNeuro
An NRx Company

12



GeNeuro Patent Portfolio

PROTECTING OUR PLATFORM. SECURING OUR FUTURE.



Geneuro holds a **global patent estate** covering our novel HERV technology platform, Timelimab (anti-HERV-W Env mAb), and in-vitro diagnostic tests.

PORTFOLIO OVERVIEW



7

Patent Families
Worldwide



150+

Patents and Applications
Issued / Pending



2027-2042

Patent Protection
Through



Broad

Composition of Matter,
Methods of Use, and
Diagnostics Covered

Our patents provide **strong protection** across our core technology platform and product pipeline.

KEY PATENT FAMILIES

	PATENT FAMILY (US PATENT OR APPLICATION NO. / WO NO.)	COVERS	GEOGRAPHIC COVERAGE
1	 Anti-HERV K Env Antibody in ALS US10723787B2	Human monoclonal antibody that binds the envelope protein of HERV-K, including GNK-301, for the treatment of ALS -- co-owned with NIH.	 US, Europe, Japan, China, Australia, Canada, Israel and other key jurisdictions
2	 Therapeutic Uses of Anti-HERV-W Antibodies US10752675B2	Use of anti-HERV-W antibodies for treatment of neurological and neuroinflammatory disorders, including ALS, Multiple Sclerosis, Psychosis / Schizophrenia, Type I Diabetes and COVID sequelae.	 US, Europe, Japan, China, Australia, Canada, Israel and other key jurisdictions
3	 In-Vitro Diagnostic Tests (HERV-W and HERV-K) US20100074894A1	Gel electrophoresis-based and other assays for detecting HERV-W and HERV-K envelope proteins and related biomarkers in biological samples.	 US, Europe, Japan, China, Australia, Canada, Israel and other key jurisdictions
4	 Nucleic Acids and Immunogens US8715656B2	Isolated nucleic acids, recombinant proteins, peptides, and immunogens derived from HERV-W envelope protein and related sequences.	 US, Europe, Japan, China, Australia, Canada, Israel and other key jurisdictions
5	 Manufacturing and Formulation US10894820B2	Processes for producing anti-HERV-W antibodies and pharmaceutical compositions suitable for clinical use.	 US, Europe, Japan, China, Australia, Canada, Israel and other key jurisdictions
6	 Precision Medicine Methods for Psychosis US20240301040A1 (Published Application)	Methods for stratifying and treating psychosis patients based on HERV-W biomarker status to improve therapeutic response.	 US, Europe, Japan, China, Australia, Canada, Israel and other key jurisdictions
7	 Antiretroviral Drugs for Retrovirus Infections EP2019/059788	Antiretroviral drug compounds and their use in treating retrovirus infections.	 US, Europe, Japan, China, Australia, Canada, Israel and other key jurisdictions



Our comprehensive IP portfolio creates a high barrier to entry and positions GeNeuro for long-term value creation.

✓ Strong Protection | ✓ Global Reach | ✓ Platform & Pipeline Coverage | ✓ Enabling Clinical and Commercial Success




SEPT 2026



GeNeuro
An NRx Company

13



GeNeuro
An NRx Company



A Chance to Change the Future of Humanity by Targeting **ALS, MS, and Psychosis**

Jonathan C. Javitt, MD, MPH | CEO



SEPTEMBER 2026



GeNeuro
An NRx Company